Concerning this news, Citi Investment Research analyst Yaron Werber commented that the study results were strong, particularly in newly diagnosed patients. However he said the regimen is complicated because it includes five different types of pills and Abbot's ritonavir can cause serious side effects when taken with some other medications.
Werber said he believes a regimen being studied by Gilead Sciences could produce similar cure rates with fewer pills. Gilead's approach uses two experimental pills, including its drug candidate sofosbuvir, as well as ribavirin.
On Aug. 27, GILD announced the U.S. Food and Drug Administration had approved Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), a complete once-daily single tablet regimen for HIV-1 infection for treatment-naive adults. Stribild, referred to as "Quad" prior to FDA approval, combines four compounds in one daily tablet: elvitegravir, an integrase inhibitor, cobicistat, a pharmacoenhancing agent, emtricitabine and tenofovir disoproxil fumarate.
Investors can anticipate that shares of GILD will continue to perform well if their experimental compounds produce similar cure rates to the one that ABT announced Monday. Their treatment focuses on both hepatitis B and C has the potential to powerfully increase their bottom line profits and earnings in the months to come.Make smarter trading decisions and provide investment ideas that could help make you richer. Bryan Ashenberg does the dirty work so you don't have to! Now let's look at another name from antiquity of yet another promising biopharmaceutical company. Isis was the name of a goddess in Ancient Egypt's religious system whose worship spread throughout the Greco-Roman world. Isis was worshipped as the ideal mother and wife as well as the patron of nature and magic. Her name literally meant "throne" as in the throne of the pharaoh. Her headdress was also a throne. As the personification of the throne, she was an important representation of the pharaoh's power. The pharaoh was said to have been her child who sat on a throne provided by his mother Isis. Quickly ascending to a pharmaceutical "throne" of great potential is what our next company, Isis Pharmaceutical (ISIS)is in the process of accomplishing. ISIS engages in the discovery and development of antisense drugs using antisense drug discovery platform. Its product pipeline comprises 26 drugs to primarily treat cardiovascular, metabolic, severe, and rare diseases, as well as cancer.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV